Kodiak Sciences (NASDAQ:KOD) Receives “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Kodiak Sciences Stock Up 4.3 %

Shares of Kodiak Sciences stock opened at $5.53 on Friday. Kodiak Sciences has a 52 week low of $1.89 and a 52 week high of $7.77. The company has a market capitalization of $290.99 million, a PE ratio of -1.52 and a beta of 2.26. The stock’s fifty day moving average is $3.36 and its two-hundred day moving average is $3.04.

Institutional Investors Weigh In On Kodiak Sciences

Large investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC purchased a new position in shares of Kodiak Sciences during the first quarter worth approximately $50,000. SG Americas Securities LLC purchased a new position in Kodiak Sciences during the 3rd quarter worth $33,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Kodiak Sciences during the 1st quarter valued at $68,000. Meeder Asset Management Inc. purchased a new stake in shares of Kodiak Sciences in the 2nd quarter worth $36,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Kodiak Sciences during the 2nd quarter worth $36,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.